Get your patient on Ozempic (Semaglutide)

Ozempic Savings Card, Coupon & Coverage 2026

>80%
of the top 10 commercial plans cover Ozempic
69%
of plans require PA
$25/mo
with Ozempic Savings Card
2
savings & assistance programs
Compare GLP-1 Alternatives
See how Ozempic stacks up on access, cost, and PA burden — the factors that affect whether your patient can actually get on therapy.
Access MetricOzempicSemaglutidezepboundmounjarowegovyrybelsus
Plan Coverage% of commercial plans>80%Best
PA Required% of plans requiring PA69%
Copay w/ SavingsWith manufacturer card
$25
Savings ProgramsTotal available2Most
Copay
Approved IndicationsFDA-approved uses
Type 2 DiabetesCardiovascular RiskChronic Kidney Disease
Get better comparisons with Prescriber.AI
See which alternative has the best coverage, lowest PA burden, and best savings for your patient's specific insurance.
See all comparisons →

Insurance Coverage

See specific coverage requirements for your patient's insurance plan.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
UnitedHealthcare (UHC)Ozempic
Covered on 4 commercial plans
PA (4/4) · Step therapy (0/4) · Qty limit (0/4)
View full coverage details
Aetna HealthOzempic
Covered on 5 commercial plans
PA (1/5) · Step therapy (1/5) · Qty limit (1/5)
View full coverage details
CIGNAOzempic
Covered on 4 commercial plans
PA (4/4) · Step therapy (0/4) · Qty limit (0/4)
View full coverage details
Coverage data sourced from MMIT. Updated monthly.

Savings & Copay Programs

Help your patients reduce out-of-pocket costs for Ozempic.
$25/month
COPAY CARD
Ozempic Savings CardEligible commercially-insured patients may pay as little as $25/month. Check program terms and enrollment eligibility.

Prior Authorization69% of plans require PA6 forms
Download the right PA form for your patient's insurance plan.

Most recent Ozempic prior authorization forms

Aetna - Louisiania Prior Authorization Request FormUpdated May 11, 2026
Aetna - Medical Exception/Prior Authorization/Precertification Request for Prescription MedicationsUpdated May 11, 2026
Humana - General Prior Authorization FormUpdated May 11, 2026
Independence Health - Select Formulary Prior Authorization Form Updated May 11, 2026
Kaiser Permanente of Colorado - Medicare Medication Request form (MRF)Colorado · Updated May 11, 2026
View all PA forms for Ozempic
Brand Resources
Formulary InformationFormulary Information resource
onehub-banner
Let us handle your prior authsJust enter your patient's info and we'll:
  • Verify eligibility with the payer.
  • Pull the right PA forms directly from the payer.
  • Submit, track & send live updates to your dashboard.
Utilize patient records to autofill forms with our AI in seconds.
Free to start · HIPAA compliant
Prescribing Information
Indications
  • As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
  • To reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction or non-fatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease.
  • To reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes mellitus and chronic kidney disease.
Dosing Titration
0.25
0.25 mgFirst 4 weeksTitration
0.5
0.5 mgAfter 4 weeksMaintenance
1
1 mg≥4 weeks laterEscalation
2
2 mg≥4 weeks laterMax dose
Subcutaneous injection · once weekly · any time of day · with or without meals. 0.25 mg is for initiation only and not effective for glycemic control. Maximum: 2 mg once weekly.
Common Side Effects
Nausea
20%
Vomiting
9%
Diarrhea
9%
Abdominal pain
6%
Constipation
3%
Contraindications
  • A personal or family history of MTC or in patients with MEN 2.
  • A serious hypersensitivity reaction to semaglutide or to any of the excipients in OZEMPIC. Serious hypersensitivity reactions including anaphylaxis and angioedema have been reported with OZEMPIC.
Full FDA Prescribing Information
Access the complete FDA-approved prescribing label for Ozempic, including approved indications, recommended dosage & administration schedules, contraindications, warnings & precautions, adverse reactions, drug interactions, and use in specific populations.

Resources

Dosage & administration

DOSAGE AND ADMINISTRATION

  • Administer once weekly at any time of day, with or without meals. (2.1 )
  • Start at 0.25 mg once weekly. After 4 weeks, increase the dosage to 0.5 mg once weekly. (2.2 )
  • If additional glycemic control is needed, increase the dosage to 1 mg once weekly after at least 4 weeks on the 0.5 mg dose. (2.2 )
  • If additional glycemic control is needed, increase the dosage to 2 mg once weekly after at least 4 weeks on the 1 mg dosage. (2.2 )
  • To reduce the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death, increase the dosage to 1 mg once weekly after at least 4 weeks on the 0.5 mg dosage. (1 , 2.2 )
  • If a dose is missed, administer within 5 days of missed dose. (2.1 )
  • Inject subcutaneously in the abdomen, thigh, or upper arm. (2.1 )

Important Administration Instructions

  • Inspect OZEMPIC visually before use. It should appear clear and colorless. Do not use OZEMPIC if particulate matter and coloration is seen.
  • Administer OZEMPIC once weekly, on the same day each week, at any time of the day, with or without meals.
  • Inject OZEMPIC subcutaneously in the abdomen, thigh, or upper arm. Instruct patients to use a different injection site each week when injecting in the same body region.
  • When using OZEMPIC with insulin, instruct patients to administer as separate injections and to never mix the products. It is acceptable to inject OZEMPIC and insulin in the same body region, but the injections should not be adjacent to each other.
  • The day of weekly administration can be changed if necessary as long as the time between two doses is at least 2 days (>48 hours).
  • If a dose is missed, administer OZEMPIC as soon as possible within 5 days after the missed dose. If more than 5 days have passed, skip the missed dose and administer the next dose on the regularly scheduled day. In each case, patients can then resume their regular once-weekly dosing schedule.

Recommended Dosage

Recommended Initiation Dosage

Initiate OZEMPIC with a dosage of 0.25 mg injected subcutaneously once weekly for 4 weeks. Follow the dosage escalation below to reduce the risk of gastrointestinal adverse reactions [see Warnings and Precautions (5.7 ), Adverse Reactions (6.1 )].

After 4 weeks on the 0.25 mg dosage, increase the dosage to 0.5 mg once weekly.

Recommended Maintenance and Maximum Dosages for Glycemic Control

The recommended maintenance dosage is 0.5 mg, 1 mg, or 2 mg, injected subcutaneously once weekly, based on glycemic control.

If additional glycemic control is needed after at least 4 weeks on the:

  • 0.5 mg dosage, the dosage may be increased to 1 mg once weekly.
  • 1 mg dosage, the dosage may be increased to 2 mg once weekly.

The maximum recommended dosage is 2 mg once weekly.

Recommended Maintenance Dosage in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease

Increase the dosage to the maintenance dosage, 1 mg once weekly, after at least 4 weeks on the 0.5 mg dosage.

PubMed™ news

5 most recent articles for Ozempic, view all articles on PubMed™
Show the latest PubMed™ articles for Ozempic

Frequently Asked Questions